Maria H. Sjogren, MD, MPH; Charles H. Hoke, MD; Leonard N. Binn, PhD; Kenneth H. Eckels, PhD; Doria R. Dubois, PhD; Lionel Lyde; Amy Tsuchida, MD; Stanley Oaks Jr., PhD; Ruth Marchwicki, BS; Wayne Lednar, MD, PhD; Robert Chloupek, MD; John Ticehurst, MD; William H. Bancroft, MD
Although hepatitis A is a disease without chronic sequelae, it is associated with serious morbidity in adults. An inactivated hepatitis A vaccine prepared at the Walter Reed Army Institute of Research was observed to successfully immunize owl monkeys (1). In a preliminary study, this vaccine was given to eight men, all of whom developed neutralizing antibody to hepatitis A virus (anti-HAV) (2). The present study was designed to confirm the vaccine's immunogenicity, to obtain additional evidence of vaccine safety, and to establish a practical dosing schedule.
Forty-two male volunteers, 18 to 50 years of age, were enrolled from among
Sjogren MH, Hoke CH, Binn LN, Eckels KH, Dubois DR, Lyde L, et al. Immunogenicity of an Inactivated Hepatitis A Vaccine. Ann Intern Med. ;114:470–471. doi: 10.7326/0003-4819-114-6-470
Download citation file:
Published: Ann Intern Med. 1991;114(6):470-471.
Gastroenterology/Hepatology, Infectious Disease, Prevention/Screening, Vaccines/Immunization, Viral Hepatitis.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use